Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2755071 | 0.86 | TSHR (0.40) | CYP1A2TSHR | |
| SCHEMBL11886190 | 0.78 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL12733693 | 0.78 | CYP1A2 (0.34) | CYP1A2 | |
| SCHEMBL2755092 | 0.74 | — | — | |
| SCHEMBL19286934 | 0.74 | — | — | |
| SCHEMBL2755099 | 0.73 | CYP2D6 (0.34) | CYP1A2TSHR | |
| SCHEMBL31346933 | 0.72 | TSHR (0.34) | CYP1A2TSHR | |
| SCHEMBL16969448 | 0.70 | TSHR (0.31) | CYP1A2TSHR | |
| SCHEMBL10287474 | 0.70 | TSHR (0.31) | CYP1A2TSHR | |
| SCHEMBL12026390 | 0.70 | CXCR4 (0.32) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962596-B2 | 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases | ARRAY BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8536193-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
| US-20110082135-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | JAK1, JAK3, JAK2 | CYP1A2 1615/4885TSHR 886/4885 |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3R5 | CYP1A2 4093/4885TSHR 3185/4885 |
| US-20110082135-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CA, AKT1S1, AKT1 | CYP1A2 3892/4885TSHR 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.